CAS 897-06-3 Anabolic Androgenic Steroids Androstadienedione Androsta-1

Description

Boldione (1,4-androstadiene-3,17-dione) is the lead innovation to arise out of the next generation of orally active prohormones. It is a direct precursor to the anabolic steroid boldenone, and displays a level of oral bioavailability far superior to any other compound, including the new 1-androstenes.

If you are unfamiliar with boldenone, it is an anabolic steroid most often found in injectable form as a veterinary medication (boldenone undecylenate). It is chemically a derivative of testosterone, characterized as a strong anabolic and low to moderately androgenic agent.

As its name indicates, Boldione is simply the “dione” form of boldenone, activated in the body by the same widely distributed 17beta-hydroxysteroid dehydrogenase enzyme that converts androstenedione to testosterone.

Boldione is truly the most advanced and potent anabolic prohormone ever developed, exhibiting several undeniable advantages over competing products

Boldione is unquestionably the most orally active prohormone ever developed. As you probably know, poor oral bioavailability is one of the most fundamental problems with prohormones. The liver processes natural steroid hormones so efficiently, that when taken orally little will make its way all the way through to the blood stream in active from. All but a small percentage of the steroid will typically be found as an inactive 17-keto steroid.

Here the 17 beta-hydroxyl group, vital to androgen binding, is removed and the compound rendered inactive. To solve this problem with pharmaceutical agents, chemists have synthetically altered most oral steroids with some form of 17-alpha alkylation (typically a methyl or ethyl addition), which virtually inhibits 17-ketosteroid reduction by occupying a carbon bond necessary for this reaction. But this type of alteration is also toxic to the liver, synthetic, and clearly not possible to use with natural prohormones.

The structure of Boldione however is intrinsically resistant to 17-ketosteroid deactivation during this first pass through the liver. The combination of its delta 1 and delta 4 double bond (1,4-Di Ene) shifts the hepatic metabolism (the 17-keto redox potential) of this compound far in favor of activation. This is made clear by studies showing Boldione to produce by far the most profound excretion of active 17beta-hydroxysteroids we have seen of any prohormone, as much as 50% of recovered urinary metabolites. Surprisingly the 17beta-hydroxyl group survives hepatic metabolism to an enormous degree. Although this is not the near 100% recovery you would expect with a synthetic agent, it is amazingly superior (by far) to every other prohormone ever developed including the 1-androstene’s.

By far the most profound excretion of active 17beta-hydroxysteroids of any prohormone, as much as 50% of recovered urinary metabolites.

Figure 1 compares the 17-beta hydroxysteroid recovery of 4-androstenedione, the new 1-androstenedione, and Boldione (1,4-androstadienedione). As you can see, the delta 1 bond alone increases active metabolite recovery considerably. However when we add the additional delta 4 bond, the recovery is far more dramatic.

Figure 1. Average percentage of 17beta-hydroxysteroid metabolites recovered from human urine after 4-Androstenedione injection, 100mg oral 1-androstenedione and 100mg oral 1,4-androstadienedione.

Usage :

Simplified hormonal drugs, from the testis or urine extracted with the role of a male hormone steroids,

norethisteron.Bol-dione is the precursor to bolde-none, and as of January 4, 2010 is a Schedule III

Controlled Substance.In 2004 the United States Congress passed the Anabolic Steroid Control Act of

2005 which placed 36 steroids and over the counter pro-hormones into schedule III of the Controlled

Substances Act. In this legislation bolde-none was classified as a controlled substance and bol-dione

remained legal.In April 2008 the United States Drug Enforcement Administration published an "Initial

Notice of Proposed Rulemaking" concerning the scheduling of three anabolic substances: bol-dione,

desoxymethyltestos-terone, and diene-dione. In 2008, at the time of the proposal, these three substances

were listed as ingredients in more than 58 dietary supplements which were available for purchase over

the counter.